Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Do you know, that buy dildos is easy and safety?
Popular Articles

FDA Approves TYVASO (Treprostinil) Inhalation Solution For The Treatment Of Pulmonary Arterial Hypertension
United Therapeutics Corporation (Nasdaq: UTHR) announced that the United States Food and Drug Administration (FDA) has approved TYVASO (treprostinil) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH) using the TYVASO Inhalation System (which includes the Optineb-ir device and accessories). TYVASO is indicated to increase walk distance in patients with NYHA Class III symptoms associated with WHO Group I PAH, which includes multiple etiologies such as idiopathic and familial PAH as well as PAH associated with scleroderma and congenital heart disease.
drugs without prescription
QIAGEN To Supply Molecular Screening Solutions To Increase Safety Of Blood Donations In Brazil
QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced that it has entered into an agreement to supply molecular sample and assay technologies for a new national, PCR-based blood screening program for HIV and Hepatitis C (HCV) in Brazil. QIAGEN will provide Bio-Manguinhos, the main provider of vaccines and diagnostics to the Brazilian Ministry of Health, with a significant volume of molecular testing solutions - sample and assay technologies, related instrumentation, operational know-how and training. Following the approval by the Brazilian patent authorities, the agreement will run for five years and contains options for subsequent extensions.
News of the day
Avoiding Hysterectomy: Major Interventional Radiology E-Collection Info Available
For the first time, the Society of Interventional Radiology has assembled a major electronic collection of professional articles about uterine artery embolization, a treatment directed toward a number of conditions involving the uterus-most often adverse health effects that may occur due to the presence of uterine fibroids. The Journal of Vascular and Interventional Radiology "virtual" collection allows health care providers and the public to view the abstracts on current research on this topic in one place, eliminating the need to search topics individually.
Sexual Health

Aphios Announces Presentation Of Phase II/III Clinical Trial Data On Zindol(R) For Cancer Chemotherapy Induced Nausea

Aphios Corporation announced that the results of a Phase II/III clinical trial of Zindol® for cancer chemotherapy induced nausea will be presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held from May 29 to June 02, 2009 in Orlando, FL. Zindol® is an enhanced ginger product. Despite the widespread use of the 5-HT3 receptor antagonist antiemetics, post-chemotherapy nausea and vomiting continue to be reported by up to 70% of patients receiving chemotherapy. Furthermore, these antiemetics have been associated with significant adverse effects, such as sedation, extra-pyramidal side effects and hypotension (associated with dopamine antagonists), as well as headache, diarrhea or constipation. A desirable attribute in any substitute or additional antiemetic medication is both efficacy and the absence of clinically significant adverse effects. Zindol® is an enhanced ginger product that is standardized by the bioactive constituents of ginger, gingerols and shogaols. Aphios" scientists and engineers utilized a proprietary polarity-guided SuperFluids™ CXF fractionation technology to establish conditions for the isolation of the active ingredients of Zindol®. The technology was then scaled-up for producing large quantities of the active ingredients utilizing patented SuperFluids™ CXP manufacturing technologies. The enhanced ginger concentrate was then formulated to achieve a specific concentration of ginger bioactives with all-natural liquid excipients designed to maximize stability and bioavailability of bioactive constituents, and encapsulated in gel capsules (LiCaps®) by Capsugel, Inc., a Pfizer subsidiary. Researchers at the University of Rochester Medical School conducted a multi-site, Phase II/III randomized, placebo-controlled, double-blind clinical trial to assess the efficacy of Zindol® (ginger capsules) for chemotherapy-related nausea in 644 cancer patients. Cancer patients who experienced nausea were randomized into four arms: placebo and 3 dose-escalation arms taking ginger capsules equivalent to 0.5, 1.0 and 1.5 grams ginger. All patients received 5-HT3 receptor antagonist antiemetics on Day 1 of all cycles. Data from the clinical trial indicates that all ginger doses significantly reduced nausea with the middle and lowest doses giving the best results. Ginger caused no side effects in this study, but patients should consult with their physicians before use. The results of the clinical trial study entitled "Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patients," will be orally presented and discussed on Saturday, May 30, 2009 from 1:00 to 4:00 p.m. in the Patient and Survivor Care session (Level 2, West Hall F5) of ASCO, Orlando, FL. Aphios Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009